Last reviewed · How we verify
Riboflavin Sodium Phosphate Injection
Riboflavin sodium phosphate is a water-soluble form of vitamin B2 that acts as a cofactor for flavin-dependent enzymes involved in cellular energy metabolism and oxidative stress reduction.
Riboflavin sodium phosphate is a water-soluble form of vitamin B2 that acts as a cofactor for flavin-dependent enzymes involved in cellular energy metabolism and oxidative stress reduction. Used for Riboflavin deficiency (ariboflavinosis), Nutritional supplementation in digestive diseases and malabsorption disorders.
At a glance
| Generic name | Riboflavin Sodium Phosphate Injection |
|---|---|
| Also known as | VibeX, Rincolin, Vitamin B2 |
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Vitamin B2 supplement / Cofactor |
| Target | Flavin-dependent enzymes (FAD/FMN-dependent oxidoreductases) |
| Modality | Small molecule |
| Therapeutic area | Nutritional deficiency / Supportive care |
| Phase | FDA-approved |
Mechanism of action
Riboflavin (vitamin B2) is an essential micronutrient that serves as a precursor for flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), which are critical cofactors for numerous oxidoreductase enzymes. The sodium phosphate salt form enhances bioavailability and allows for parenteral administration. It supports mitochondrial function, antioxidant defense systems, and energy production through the electron transport chain.
Approved indications
- Riboflavin deficiency (ariboflavinosis)
- Nutritional supplementation in digestive diseases and malabsorption disorders
Common side effects
- Injection site reactions
- Allergic reactions
- Yellow discoloration of urine
Key clinical trials
- Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (PHASE3)
- The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer (PHASE3)
- Tolerability and Efficacy of RJX in Patients With COVID-19 (PHASE1, PHASE2)
- Epi-On Corneal Crosslinking for Keratoconus (PHASE4)
- Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: